Trial Profile

Mesenchymal Stem Cell Extracellular Vesicles for the Treatment of Recessive Dystrophic Epidermolysis Bullosa Wounds

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGLE 103 (Primary)
Indications Epidermolysis bullosa dystrophica
Focus Adverse reactions; Therapeutic Use
Sponsors Aegle Therapeutics

Most Recent Events

25 Jun 2025 Inclusion criteria is updated to decrease the lower age limit from 6 years to 6 months, thus including infants also as subjects in this study.
25 Jun 2025 Planned number of patients changed from 10 to 8.
25 Jun 2025 Planned End Date changed from 1 Sep 2025 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com